Pds Biotechnology Corp Stock In The News

PDSB Stock  USD 1.24  0.08  6.06%   
Our overall analysis of PDS Biotechnology's news coverage and content from conventional and social sources shows investors' bearish mood towards PDS Biotechnology Corp. The specific impact of PDS Biotechnology news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of PDS Biotechnology's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using PDS Biotechnology headlines in addition to utilizing other, more conventional financial analysis modules. Check out PDS Biotechnology Backtesting and PDS Biotechnology Hype Analysis.

PDS Biotechnology Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
https://www.globenewswire.com/news-release/2025/03/25/3048687/37149/en/PDS-Biotech-Leadership-to-Present-at-2025-CAGLA-NeauxCancer-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
https://www.globenewswire.com/news-release/2025/03/14/3042975/0/en/Life-Science-Virtual-Investor-Forum-Presentations-Now-Available-for-Online-Viewing.html
 Bullish
Macroaxis News: globenewswire.com
Life Sciences Investor Forum Agenda Announced for March 13th
https://www.globenewswire.com/news-release/2025/03/12/3041653/0/en/Life-Sciences-Investor-Forum-Agenda-Announced-for-March-13th.html
 Bullish
Macroaxis News: globenewswire.com
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
https://www.globenewswire.com/news-release/2025/03/07/3038953/37149/en/PDS-Biotech-Initiates-VERSATILE-003-Phase-3-Clinical-Trial-Evaluating-Versamune-HPV-in-HPV16-Positive-Head-and-Neck-Cancer.html
 Bullish
Macroaxis News: globenewswire.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
https://www.globenewswire.com/news-release/2025/02/24/3031069/37149/en/PDS-Biotech-Announces-Circulating-Tumor-DNA-Results-for-Versamune-HPV-in-IMMUNOCERV-Trial-Published-in-Clinical-Cancer-Research.html
 Neutral
Yahoo News
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
https://finance.yahoo.com/news/pds-biotechnology-corp-pdsb-q3-070814635.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
https://www.globenewswire.com/news-release/2023/11/28/2786835/37149/en/PDS-Biotech-Appoints-Lars-Boesgaard-as-Chief-Financial-Officer.html
 Bullish
Macroaxis News: globenewswire.com
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2023/11/14/2779977/37149/en/PDS-Biotech-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Announces Updated Survival D...
https://www.globenewswire.com/news-release/2023/11/09/2777276/37149/en/PDS-Biotech-Announces-Updated-Survival-Data-from-NCI-Led-Phase-2-Clinical-Trial-of-PDS0101-Based-Triple-Combination-Therapy-in-Advanced-HPV16-Positive-Cancer-Patients-which-Show-75.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/07/2775014/37149/en/PDS-Biotechnology-Announces-Conference-Call-and-Webcast-for-Third-Quarter-2023-Financial-Results.html
 Neutral

PDS Biotechnology Corp Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide PDS and other traded companies coverage with news coverage. We help investors stay connected with PDS headlines for the 26th of March to make an informed investment decision based on correlating the impacts of news items on PDS Stock performance. Please note that trading solely based on the PDS Biotechnology Corp hype is not for everyone as timely availability and quick action are needed to avoid losses.
PDS Biotechnology's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help PDS Biotechnology Corp investors visualize upcoming and past events in order to time the market based on PDS Biotechnology Corp noise-free hype analysis.
PDS Biotechnology stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the PDS earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about PDS Biotechnology that are available to investors today. That information is available publicly through PDS media outlets and privately through word of mouth or via PDS internal channels. However, regardless of the origin, that massive amount of PDS data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PDS Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PDS Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PDS Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PDS Biotechnology alpha.

PDS Largest EPS Surprises

Earnings surprises can significantly impact PDS Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-10
2021-09-30-0.2-0.24-0.0420 
2020-08-13
2020-06-30-0.23-0.190.0417 
2021-05-13
2021-03-31-0.19-0.140.0526 
2024-05-15
2024-03-31-0.37-0.30.0718 
2022-08-08
2022-06-30-0.28-0.20.0828 
2024-03-27
2023-12-31-0.44-0.350.0920 
View All Earnings Estimates

PDS Biotechnology Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to PDS Biotechnology Corp Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
25th of March 2025
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
at gurufocus.com 
Gurufocus Stories at Macroaxis
18th of March 2025
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
at gurufocus.com 
Gurufocus Stories at Macroaxis
13th of March 2025
PDS Biotech Announces FDA Clearance of IND Application for Combi
at gurufocus.com 
Yahoo News
10th of March 2025
Synaptics Extends Edge AI Portfolio with High-Performance AdaptiveMCUs for Multimodal Cont...
at finance.yahoo.com 
news
7th of March 2025
Acquisition by Sykes Richard of 9000 shares of PDS Biotechnology at 2.86 subject to Rule 1...
at newswire.com 
Gurufocus Stories at Macroaxis
4th of March 2025
Insider Buying Stephen Glover Acquires Additional Shares of PDS Biotechnology Corp
at gurufocus.com 
news
27th of February 2025
HC Wainwright Reiterates Buy Rating for PDS Biotechnology
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
26th of February 2025
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinica...
at gurufocus.com 
Yahoo News
24th of February 2025
PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial ...
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PDS Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PDS Biotechnology's short interest history, or implied volatility extrapolated from PDS Biotechnology options trading.
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out PDS Biotechnology Backtesting and PDS Biotechnology Hype Analysis.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.45)
Return On Equity
(1.74)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.